AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today presented for the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Alector Initiates Phase 1 Trial of AL002 for Treatment of Patients with Alzheimer’s DiseaseNovember 15, 2018 7:08 AM AbbVie Presents Positive Phase 3 Data Demonstrating Investigational Elagolix Reduces Heavy Menstrual Bleeding in Women with Uterine Fibroids at 2018 AAGL Global CongressNovember 14, 2018 5:35 PM